scholarly journals Soluble epoxide hydrolase inhibition: a novel therapeutic strategy in alcoholic liver disease.

2020 ◽  
Author(s):  
Jeffrey Warner
Keyword(s):  
Liver Disease ◽  
Alcoholic Liver Disease ◽  
Epoxide Hydrolase ◽  
Therapeutic Strategy ◽  
Soluble Epoxide Hydrolase ◽  
Novel Therapeutic

Protective effects of fucoidan against ethanol-induced liver injury through maintaining mitochondria function and mitophagy balance in rats.

2021 ◽  
Author(s):  
Huichao Zhao ◽  
Shuang Liu ◽  
Hui Zhao ◽  
Meilan Xue ◽  
Huaqi Zhang ◽  
...  
Keyword(s):  
Liver Disease ◽  
Liver Injury ◽  
Alcoholic Liver Disease ◽  
Therapeutic Strategy ◽  
Hepatic Lesion ◽  
Protective Effects ◽  
Regulatory Effects

For alcoholic liver disease (ALD), mitophagy was reported as a promising therapeutic strategy to alleviate the hepatic lesion elicited by ethanol. This study was to investigate the regulatory effects of...

scholarly journals Lipidomic profiling reveals soluble epoxide hydrolase as a therapeutic target of obesity-induced colonic inflammation

2018 ◽  
Vol 115 (20) ◽  
pp. 5283-5288 ◽  
Author(s):  
Weicang Wang ◽  
Jun Yang ◽  
Jianan Zhang ◽  
Yuxin Wang ◽  
Sung Hee Hwang ◽  
...  
Keyword(s):  
Fatty Acid ◽  
Therapeutic Target ◽  
Epoxide Hydrolase ◽  
Soluble Epoxide Hydrolase ◽  
Colon Tissue ◽  
Colonic Inflammation ◽  
Obesity Epidemic ◽  
Genetic Ablation ◽  
Endogenous Lipid ◽  
Novel Therapeutic

Obesity is associated with enhanced colonic inflammation, which is a major risk factor for colorectal cancer. Considering the obesity epidemic in Western countries, it is important to identify novel therapeutic targets for obesity-induced colonic inflammation, to develop targeted strategies for prevention. Eicosanoids are endogenous lipid signaling molecules involved in regulating inflammation and immune responses. Using an LC-MS/MS–based lipidomics approach, we find that obesity-induced colonic inflammation is associated with increased expression of soluble epoxide hydrolase (sEH) and its eicosanoid metabolites, termed fatty acid diols, in colon tissue. Furthermore, we find that pharmacological inhibition or genetic ablation of sEH reduces colonic concentrations of fatty acid diols, attenuates obesity-induced colonic inflammation, and decreases obesity-induced activation of Wnt signaling in mice. Together, these results support that sEH could be a novel therapeutic target for obesity-induced colonic inflammation and associated diseases.

scholarly journals Small Molecule Soluble Epoxide Hydrolase Inhibitors in Multitarget and Combination Therapies for Inflammation and Cancer

Molecules ◽  
2020 ◽  
Vol 25 (23) ◽  
pp. 5488
Author(s):  
Amarjyoti Das Mahapatra ◽  
Rinku Choubey ◽  
Bhaskar Datta
Keyword(s):  
Small Molecule ◽  
Combination Chemotherapy ◽  
Epoxide Hydrolase ◽  
Therapeutic Strategy ◽  
Soluble Epoxide Hydrolase ◽  
Epoxyeicosatrienoic Acids ◽  
Protective Properties ◽  
Soluble Epoxide Hydrolase Inhibitors ◽  
Synthetic Scaffolds ◽  
Structural Insights

The enzyme soluble epoxide hydrolase (sEH) plays a central role in metabolism of bioactive lipid signaling molecules. The substrate-specific hydrolase activity of sEH converts epoxyeicosatrienoic acids (EETs) to less bioactive dihydroxyeicosatrienoic acids. EETs exhibit anti-inflammatory, analgesic, antihypertensive, cardio-protective and organ-protective properties. Accordingly, sEH inhibition is a promising therapeutic strategy for addressing a variety of diseases. In this review, we describe small molecule architectures that have been commonly deployed as sEH inhibitors with respect to angiogenesis, inflammation and cancer. We juxtapose commonly used synthetic scaffolds and natural products within the paradigm of a multitarget approach for addressing inflammation and inflammation induced carcinogenesis. Structural insights from the inhibitor complexes and novel strategies for development of sEH-based multitarget inhibitors are also presented. While sEH inhibition is likely to suppress inflammation-induced carcinogenesis, it can also lead to enhanced angiogenesis via increased EET concentrations. In this regard, sEH inhibitors in combination chemotherapy are described. Urea and amide-based architectures feature prominently across multitarget inhibition and combination chemotherapy applications of sEH inhibitors.

MAIT cells: a novel therapeutic target for alcoholic liver disease?

Gut ◽  
2017 ◽  
Vol 67 (5) ◽  
pp. 784-786 ◽  
Author(s):  
Bin Gao ◽  
Jing Ma ◽  
Xiaogang Xiang
Keyword(s):  
Liver Disease ◽  
Alcoholic Liver Disease ◽  
Therapeutic Target ◽  
Mait Cells ◽  
Novel Therapeutic

scholarly journals Soluble Epoxide Hydrolase: A Novel Therapeutic Target in Stroke

2007 ◽  
Vol 27 (12) ◽  
pp. 1931-1940 ◽  
Author(s):  
Wenri Zhang ◽  
Ines P Koerner ◽  
Ruediger Noppens ◽  
Marjorie Grafe ◽  
Hsing-Ju Tsai ◽  
...  
Keyword(s):  
Therapeutic Target ◽  
Epoxide Hydrolase ◽  
Soluble Epoxide Hydrolase ◽  
Novel Therapeutic
Sign in / Sign up

Export Citation Format

Share Document